Noxopharm sees important board movements

Company News

by Rachael Jones

Noxopharm (ASX:NOX) is seeing some movement to their board with Group CEO and Executive Director Graham Kelly moving to Executive Chairman.

Peter Marks is moving from Non-Executive Chairman to Non Executive Deputy Chairman.

The changes have been prompted by a strategic decision to start the process of raising the Company’s profile in the US including a listing of its securities on the Nasdaq.

Medical Director Beata Niechoda will join as a Special Advisor to the Board.

Graham and Beata will complement the function of Greg van Wyk as Noxopharm CEO and CMO, and guide Veyonda? through clinical phases.

Greg will be assisted by the appointment of Jeanette Bell as Chief Operating Officer.

Shares in Noxopharm (ASX:NOX) closed flat at 48 cents on Thursday. 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.